- Home
- CLGN vs CARM Comparison
CLGN vs CARM Comparison
Compare CLGN & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- CARM
- Stock Information
- Founded
- CLGN 2004
- CARM 2016
- Country
- CLGN Israel
- CARM United States
- Employees
- CLGN N/A
- CARM N/A
- Industry
- CLGN Industrial Specialties
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- CLGN Health Care
- CARM Health Care
- Exchange
- CLGN Nasdaq
- CARM Nasdaq
- Market Cap
- CLGN 19.1M
- CARM 16.4M
- IPO Year
- CLGN N/A
- CARM N/A
- Fundamental
- Price
- CLGN $2.31
- CARM $0.39
- Analyst Decision
- CLGN Strong Buy
- CARM Hold
- Analyst Count
- CLGN 2
- CARM 5
- Target Price
- CLGN $11.50
- CARM $0.90
- AVG Volume (30 Days)
- CLGN 69.8K
- CARM 734.3K
- Earning Date
- CLGN 08-19-2025
- CARM 08-07-2025
- Dividend Yield
- CLGN N/A
- CARM N/A
- EPS Growth
- CLGN N/A
- CARM N/A
- EPS
- CLGN N/A
- CARM N/A
- Revenue
- CLGN $2,472,000.00
- CARM $19,964,000.00
- Revenue This Year
- CLGN $1,999.42
- CARM N/A
- Revenue Next Year
- CLGN $69.81
- CARM N/A
- P/E Ratio
- CLGN N/A
- CARM N/A
- Revenue Growth
- CLGN N/A
- CARM 32.45
- 52 Week Low
- CLGN $1.31
- CARM $0.14
- 52 Week High
- CLGN $5.45
- CARM $1.27
- Technical
- Relative Strength Index (RSI)
- CLGN 65.19
- CARM 49.21
- Support Level
- CLGN $2.16
- CARM $0.38
- Resistance Level
- CLGN $2.28
- CARM $0.41
- Average True Range (ATR)
- CLGN 0.18
- CARM 0.03
- MACD
- CLGN 0.11
- CARM -0.01
- Stochastic Oscillator
- CLGN 86.24
- CARM 26.92
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.